Framatome and IBA To Partner To Advance Scale-Production Of Astatine-211
Framatome (ENS Corporate Member) and IBA (Ion Beam Applications S.A., EURONEXT) announced the signature of a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (211At), an alpha-emitting radioisotope across Europe and the United States.
211At is a highly promising radioisotope currently being investigated for its potential in targeted alpha-therapies in oncology.
The collaboration between Framatome and IBA aims to meet the growing demand for 211At and secure its timely availability for advanced cancer treatments by building a reliable and sustainable network of cutting-edge specialized alpha-emitting cyclotrons.
The first milestone in this collaboration will be the establishment of a dedicated production pilot facility, set to be installed by 2027-2028. Framatome will make a financial investment in the partnership, with IBA contributing equipment.
The facility will be located in the Pays de la Loire region in France, leveraging the region’s strong nuclear medicine research ecosystem and industrial expertise.
This partnership with IBA is a significant step toward transforming cancer care through targeted alpha therapy. The secure, scalable, and timely supply of Astatine-211 is vital for addressing unmet medical needs, and we are committed to building a robust production network to serve the growing demand.
François Gauché, Vice President of Framatome Healthcare, said.
Read the full Framatome Press Release.
Nuclear medicine and medical isotopes benefit thousands of patients every day in current clinical practice and have great potential for future clinical challenges.
At ENS, we actively highlight the potential, progress, and challenges of nuclear medicine through dedicated events and discussions.
Here is an overview of our recent initiatives:
- Beating Cancer – Turning the Tide with Medical Isotopes (2023)
Special Newsletter.
YouTube Recording - An inspiring interview with Sarah Baatout, “Advancing Healthcare – Exploring the Frontiers of Nuclear Medicine” (2024)
- Meet the winner of the ENS HSC PhD Award 2024, awarded for her dissertation on innovative radioisotope applications in nuclear medicine
